# Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors

> **NCT04809012** · PHASE2 · WITHDRAWN · sponsor: **Sorrento Therapeutics, Inc.**

## Conditions studied

- Solid Tumor
- Refractory Tumor
- Relapsed Solid Tumor

## Interventions

- **BIOLOGICAL:** STI-3031

## Key facts

- **NCT ID:** NCT04809012
- **Lead sponsor:** Sorrento Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-06
- **Primary completion:** 2024-06
- **Final completion:** 2024-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Intended to be replaced with another Protocol
- **Last updated:** 2022-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04809012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04809012, "Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04809012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*